4th Palermo Conference on INNOVATIVE THERAPIES FOR LYMPHOID MALIGNANCIES
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raiola, A.
Right arrow Articles by Bacigalupo, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raiola, A.
Right arrow Articles by Bacigalupo, A
Haematologica, Vol 85, Issue 1, 59-62
Copyright © 2000 by Ferrata Storti Foundation

Clinical Trial

Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria

AM Raiola, MT Van Lint, T Lamparelli, F Gualandi, F Benvenuto, O Figari, N Mordini, G Berisso, S Bregante, F Frassoni, and A Bacigalupo

Dipartimento di Ematologia, Ospedale San Martino, largo R. Benzi 10, 16132 Genoa, Italy. apbacigalupo@smartino.ge.it.

BACKGROUND AND OBJECTIVE: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disease of the hemopoietic stem cell (HSC) characterized by intravascular hemolysis and increased risk of venous thrombosis. There are different therapeutic approaches for PNH which do not cure the disease, but can decrease its complications. Allogeneic bone marrow transplantation (BMT) may cure PNH. We reports here our experience of seven PNH patients who underwent allogeneic BMT. DESIGN AND METHODS: Between January 1991 and January 1999 seven patients with PNH, aged 23 to 37, were transplanted with unmanipulated bone marrow from HLA identical siblings. Median time from diagnosis to BMT was 2.5 years (range: 1-16). All patients were transfusion-dependent and had received various treatments before BMT: steroids, vitamins, cyclosporin A (CyA), growth factors. One patient had also been treated with anti-thymocyte globulin. One patient was HbsAg positive and one anti-HCV positive. At the time of BMT the median value of hemoglobin (Hb) was 9 g/dL (range 6.5-11), white blood cells 5&10(9)/L (range: 2.9-7.7), platelets 97&10(9)/L (range: 31-355), LDH: 2726 U/L. The conditioning regimen was cyclophosphamide (160 mg/kg) and busulfan (10-14 mg/kg), followed by unmanipulated bone marrow (median of 5&10(8) cells/kg) and CyA (+MTX in two patients) for prophylaxis of graft-versus-host disease (GvHD). RESULTS: All seven patients are alive, full chimeras, with complete hematologic recovery and no evidence of PNH, at a median follow up of 51 months post-BMT (6-103). Time to achieve a granulocyte count of 0.5&10(9)/L, platelets 30&10(9)/L and Hb 10 g/dL was respectively 16, 19 and 22 days. Acute GvHD was limited or mild in six patients, and severe in one. Chronic GvHD was extensive in two patients. INTERPRETATION AND CONCLUSIONS: This study confirms that HLA identical sibling BMT is an effective therapeutic option for PNH, also in the hemolytic phase of the disease: it also suggests that HBV and HCV infections are not an absolute contraindication.


This article has been cited by other articles:


Home page
 BloodHome page
C. Parker, M. Omine, S. Richards, J.-i. Nishimura, M. Bessler, R. Ware, P. Hillmen, L. Luzzatto, N. Young, T. Kinoshita, et al.
Diagnosis and management of paroxysmal nocturnal hemoglobinuria
Blood, December 1, 2005; 106(12): 3699 - 3709.
[Full Text] [PDF]

Home page
 BloodHome page
J.-i. Nishimura, K. L. Phillips, R. E. Ware, S. Hall, L. Wilson, T. L. Gentry, T. A. Howard, Y. Murakami, M. Shibano, T. Machii, et al.
Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype
Blood, May 15, 2001; 97(10): 3004 - 3010.
[Abstract] [Full Text] [PDF]